Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

Hispanics With HIV Face Higher Risk for HPV-Related Cancer

But five-year survival was above 50 percent among HIV-infected Hispanics across HPV-related cancer types

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

WEDNESDAY, Oct. 24, 2018 (HealthDay News) -- HIV-infected Hispanics have an increased risk for human papillomavirus (HPV)-related cancers than Hispanics in the general population, according to a study published online Oct. 22 in Cancer.

Ana P. Ortiz, Ph.D., from the University of Puerto Rico in San Juan, and colleagues used data from the HIV/AIDS Cancer Match Study to estimate HPV-related cancer risk in HIV-infected Hispanics and the general U.S. Hispanic population.

The researchers identified 502 HPV-related cancers over 864,067 person-years of follow-up among HIV-infected Hispanics. The risk for HPV-related cancers was higher among HIV-infected Hispanics than in the general population (standardized incidence ratio range, 3.59 [cervical cancer] to 18.7 [anal cancer in men]); however, the researchers did not observe this finding for oropharyngeal cancer. Hispanic HIV-infected women had higher cervical cancer rates than non-Hispanic whites (NHWs; incidence rate ratio [IRR], 1.7) but lower vulvar cancer rates than NHWs (IRR, 0.4) and non-Hispanic blacks (NHBs; IRR, 0.62). Hispanic HIV-infected men had higher penile cancer rates than NHWs (IRR, 2.6) but lower anal cancer rates than NHWs (IRR, 0.54) and NHBs (IRR, 0.65). Five-year survival was greater than 50 percent among HIV-infected Hispanics across HPV-related cancer types, with no major differences by racial/ethnic group.

"HPV vaccination should be promoted among HIV-infected individuals to reduce the burden of HPV-related cancers," the authors write.

Abstract/Full Text (subscription or payment may be required)

Last Updated: